Results 191 to 200 of about 979,452 (291)

A Compound Screen Based on Isogenic hESC‐Derived β Cell Reveals an Inhibitor Targeting ZnT8‐Mediated Zinc Transportation to Protect Pancreatic β Cell from Stress‐Induced Cell Death

open access: yesAdvanced Science, EarlyView.
Pancreatic β cell loss by cellular stress contributes to diabetes pathogenesis. The study demonstrates that WFS1–ZnT8–zinc axis regulates vicious cycle of zinc transportation and cellular stress in pancreatic β cell. Based on that, the study applies a strategy for compound screening targeting ZnT8 based on human models, and identifies anisomycin, as a ...
Rui Hu   +19 more
wiley   +1 more source

Verteporfin‐Mediated In Situ Nanovaccine Based on Local Conventional‐Dose Hypofractionated Radiotherapy Enhances Antitumor and Immunomodulatory Effect

open access: yesAdvanced Science, EarlyView.
Here gelatinase‐responsive methoxypolyethyleneglycol–PVGLIG–polycaprolactone (mPEG–PVGLIG–PCL) nanoparticles’ loading verteporfin (N@VP) is developed, enhancing radiotherapy via X‐ray‐triggered singlet oxygen generation. Combined with 2 Gy (gray, a radiation dose unit) irradiation, N@VP achieves antitumor efficacy comparable to 8 Gy, and also promotes ...
Zhifan Zhang   +16 more
wiley   +1 more source

NKX2‐5/LHX1 and UHRF1 Establishing a Positive Feedback Regulatory Circuitry Drives Esophageal Squamous Cell Carcinoma through Epigenetic Dysregulation

open access: yesAdvanced Science, EarlyView.
The study identifies a positive feed‐forward loop that intertwines DNA methylation regulator UHRF1 with Homeobox genes‐NKX2‐5/LHX1 via UMRs as a critical driver of ESCC. Pharmacological inhibition of UHRF1 and DNMT activity inhibits ESCC growth, which may represent a promising therapeutic approach to treat ESCC patients dependent on NKX2‐5/LHX1/UHRF1 ...
Xukun Li   +13 more
wiley   +1 more source

Targeting Splenic Myeloid Cells with Nanobiologics to Prevent Postablative Pancreatic Cancer Recurrence via Inducing Antitumor Peripheral Trained Immunity

open access: yesAdvanced Science, EarlyView.
Using a preclinical pancreatic cancer model, we identified that tumor progression restructures splenic immunity via myeloid cell expansion. MDCa@RBC‐Alipo nanobiologics were engineered to epigenetically and metabolically reprogram splenic myeloid cells, alleviating post‐ablation immunosuppression.
Shengbo Wu   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy